Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 209,669	$ 287,496
Prepaid expenses and other current assets (including related party amounts of $0 and $82, respectively)	1,669	3,872
Total current assets	211,338	291,368
Property, plant and equipment, net	803	986
Operating lease right-of-use assets	2,147	2,373
Other long-term assets	291	384
Total assets	214,579	295,111
Current liabilities:
Accounts payable (including related party amounts of $124 and $173, respectively)	5,401	16,782
Accrued clinical trial expenses	14,238	19,997
Accrued expenses (including related party amounts of $1,505 and $734, respectively)	8,845	10,606
Accrued interest	302	312
Current portion of long-term debt	10,345	7,353
Operating lease liabilities, current	480	474
Total current liabilities	39,611	55,524
Long-term debt, net of discount	37,340	39,634
Operating lease liabilities	1,375	1,557
Other long-term liabilities	4,125	4,125
Total liabilities	82,451	100,840
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at June 30, 2021 and December 31, 2020 ; no shares issued and outstanding at June 30, 2021 and December 31, 2020
Common stock, $0.0001 par value; authorized shares — 400,000,000; issued shares — 31,329,613 and 31,262,769 at June 30, 2021 and December 31, 2020, respectively; outstanding shares — 29,186,169 and 28,516,010 at June 30, 2021 and December 31, 2020, respectively	3	3
Additional paid-in capital	589,007	579,755
Accumulated deficit	(456,882)	(385,487)
Total stockholders’ equity	132,128	194,271
Total liabilities and stockholders’ equity	$ 214,579	$ 295,111